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the trial to assess for differences in clinically sig-
nificant cancer in the subgroups with different 
coil strengths. Eighteen of 62 men in the 1.5-T 
MRI group (29%; 95% confidence interval [CI], 
19 to 41) and 75 of 184 men in the 3.0-T MRI 
group (41%; 95% CI, 34 to 48) had clinically sig-
nificant cancer. Since men were not randomly 
assigned to undergo MRI performed with 1.5-T 
or 3.0-T scanners, the differences observed may 
be confounded by other factors. The Prostate MRI 
Imaging Study (PROMIS), a multicenter study in-
volving 576 men, used only 1.5-T MRI machines 
and showed that MRI was superior to transrectal 
ultrasonography–guided prostate biopsy for the 
detection of clinically significant cancer.1
We agree with Vickers and Ehdaie that urolo-
gists have been performing transrectal ultraso-
nography–guided biopsies for decades, but we 
would assert that tradition alone is an insuffi-
cient reason not to change practice in the face of 
growing scientific evidence. Transrectal ultraso-
nography–guided biopsy has been shown to miss 
more than 50% of clinically significant cancers 
in men.1 Many men undergo repeat transrectal 
ultrasonography–guided biopsy, with a 2 to 4% 
risk of sepsis and costs to health services.2 The 
Danish Cancer Registry study cited by Vickers 
et al. showed that in 17% of men with negative 
results on transrectal ultrasonography–guided bi-
opsy who underwent repeat biopsy, prostate can-
cer of Gleason sum 8 was missed.3 This is unde-
sirable for a diagnostic test. In the PRECISION 
trial, with the use of the same threshold for 
clinically significant cancers as described by 
Vickers et al., MRI with or without targeted bi-
opsy detected 6% (95% CI, 1 to 10) more cancers 
of Gleason sum 8 or worse than transrectal ultra-
sonography–guided biopsy. In addition, 13% 
(95% CI, 7 to 19) fewer men in the MRI-targeted 
biopsy group than in the standard-biopsy group 
received a diagnosis of clinically insignificant 
cancer — a diagnosis that can lead to consider-
able overtreatment and harm to men. Other 
studies have also shown that MRI-targeted biopsy 
detects more clinically significant cancer and less 
clinically insignificant cancer than transrectal 
ultrasonography–guided biopsy.4 We acknowledge 
that there is uncertainty as to the prognosis of 
clinically significant cancer identified by MRI-
targeted biopsy,5 although future studies, and 
not conjecture, may ascertain the risk of death 
among these patients.
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Single-Inhaler Triple versus Dual Therapy in Patients with COPD
To the Editor: In the randomized Informing 
the Pathway of COPD Treatment (IMPACT) trial 
involving more than 10,000 patients with chronic 
obstructive pulmonary disease (COPD), Lipson 
and colleagues (May 3 issue)1 compared a once-
daily combination of f luticasone furoate (an 
 inhaled glucocorticoid), umeclidinium (a long-
acting muscarinic antagonist [LAMA]), and vilan-
terol (a long-acting β2-agonist [LABA]) with an 
inhaled glucocorticoid–LABA or a LABA–LAMA 
combination. The primary outcome was the 
 annual rate of moderate or severe COPD exacer-
bations. Since a large fraction of COPD exacerba-
tions are infectious in origin,2 we wonder whether 
there were any differences among the three groups 
with respect to the proportion of patients who 
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had received annual influenza and pneumococcal 
vaccinations.
A meta-analysis of two randomized trials in-
volving patients with COPD3 showed that sea-
sonal influenza vaccine had significantly better 
efficacy in preventing exacerbations than place-
bo. In addition, in a recently updated Cochrane 
meta-analysis, pneumococcal vaccination was as-
sociated with significant efficacy not only against 
community-acquired pneumonia but also in the 
prevention of acute exacerbations in patients 
with COPD.4
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To the Editor: Lipson and colleagues mention 
differences between the FLAME trial1,2 and the 
IMPACT trial with respect to trial design. These 
differences were not likely to account for the dif-
ferences in prevention of exacerbations. During 
the 4-week run-in period in the FLAME trial 
(when all patients received inhaled tiotropium), 
only 3.6% of the patients discontinued treat-
ment because of exacerbations, and no additional 
patients were excluded because of findings on 
spirometry.
A critical difference was the careful exclusion 
of patients with any history of asthma in the 
FLAME trial, whereas in the IMPACT trial, a his-
tory of asthma was acceptable.3 Many of the 
patients with moderate airf low limitation and 
frequent exacerbations included in the IMPACT 
trial may have had a history of asthma. In pa-
tients with concomitant asthma, abrupt with-
drawal of inhaled glucocorticoids would plausi-
bly lead to an acute increase in symptoms and 
early exacerbations4 and would affect the patients’ 
health status and all clinical outcomes during 
follow-up.
Trials involving patients with COPD that in-
clude treatment groups that do not receive in-
haled glucocorticoids should have a standardized 
run-in period and exclude patients with con-
comitant asthma. Otherwise, there are potential 
biases and clinically significant harmful effects 
of withdrawal of inhaled glucocorticoids in such 
patients.
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To the Editor: The IMPACT trial showed a sig-
nificantly lower rate of moderate or severe COPD 
exacerbations among patients who received triple 
combination therapy with an inhaled glucocor-
ticoid–LABA–LAMA (0.91 per year) than among 
those who received LABA–inhaled glucocorticoid 
combination therapy (1.07 per year) or LABA–
LAMA combination therapy (1.21 per year). The 
results of this trial should be interpreted with 
caution, since more than 70% of the patients 
were receiving a regimen containing inhaled glu-
cocorticoids at randomization. Magnussen et al. 
previously established the safety of withdrawal of 
inhaled glucocorticoids in a three-step with-
drawal process over a 12-week period in patients 
with stable COPD.1
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In the present trial, inhaled glucocorticoid 
therapy was abruptly discontinued at random-
ization. All included patients had symptomatic 
COPD at baseline, and the patient population 
was not similar to that in the trial conducted by 
Magnussen et al. To accurately address the ques-
tion of the efficacy of triple therapy as compared 
with LABA–LAMA combination therapy, patients 
included in the trial should either not have been 
receiving inhaled glucocorticoid therapy at base-
line or appropriate procedures for the withdrawal 
of inhaled glucocorticoids should have been 
followed.
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The authors reply: We agree with Rolla and 
Brussino regarding the importance of vaccina-
tion in patients with COPD. In the IMPACT trial, 
we advocated for the best care of the patients and 
recommended that if these vaccinations were not 
up to date, all patients should be offered influ-
enza vaccine, pneumococcal vaccine, or both. 
Unfortunately, overall global vaccination rates 
were low, and only 17% of the patients reported 
having received vaccinations. The vaccination 
rates were similar across the trial groups (17% in 
the triple-therapy group, 16% in the fluticasone 
furoate–vilanterol group, and 16% in the umecli-
dinium–vilanterol group). We think that further 
efforts should be made to help improve overall 
vaccination rates in clinical care.
We disagree with Wedzicha and colleagues 
and think that differences in trial design and 
patient populations clearly explain the differ-
ences between the FLAME trial1 and the IMPACT 
trial. Wedzicha and colleagues also promulgate 
a circular argument, because if they think that 
withdrawal of inhaled glucocorticoids is harm-
ful, they must also think that inhaled glucocor-
ticoids are beneficial in some patients who have 
COPD. The evaluated trials have different patient 
populations; approximately 30% of the patients 
in the FLAME trial and approximately 70% in 
the IMPACT trial had Global Initiative for Chron-
ic Obstructive Lung Disease severe (category D) 
disease (i.e., they had symptoms and had had 
two or more moderate or one severe exacerba-
tion in the previous year), according to the cur-
rent classification.2 Our trial was designed to 
study a typical COPD population, with results 
that would be generalizable to clinical practice. 
Because of the exclusion of a current diagnosis 
of asthma and the use of the same criteria as 
previous trials, with inclusion of a history of 
asthma,3 the population in the IMPACT trial is 
easily recognized by practicing physicians. All 
patients met American Thoracic Society–Euro-
pean Respiratory Society criteria4 for COPD, had 
a mean age of 65 years, had fixed airf low limi-
tation with a mean forced expiratory volume in 
1 second of 45.5% of the predicted normal value, 
and had a history of heavy smoking (approxi-
mately 47 pack-years). The investigators in our 
trial excluded patients whose symptoms were not 
due to COPD. In contrast, the FLAME trial en-
rolled a population of patients who were unlikely 
to benefit from inhaled glucocorticoids, since the 
investigators enrolled only those patients who did 
not have COPD exacerbations during a 4-week 
run-in period with tiotropium. This effectively 
biased the trial against finding a benefit associ-
ated with inhaled glucocorticoids. The FLAME 
trial also excluded patients with blood eosino-
phil levels greater than 600 cells per microliter. 
The FLAME trial and the IMPACT trial involved 
different patient populations; clinicians should 
consider these differences in decision making.
Petite questions whether withdrawal of in-
haled glucocorticoids contributed to the efficacy 
observed with triple therapy as compared with 
dual therapy. Our trial was not a glucocorticoid-
withdrawal trial. Approximately 70% of the pa-
tients entered the trial while receiving an inhaled 
glucocorticoid–containing regimen, yet only 20% 
were randomly assigned to LAMA–LABA. There-
fore, only 14% of the participants in our trial 
had withdrawal of inhaled glucocorticoids. This 
did not contribute significantly to the observed 
trial effects, and we continued to see COPD ex-
acerbations throughout the trial, not only in the 
The New England Journal of Medicine 
Downloaded from nejm.org on February 19, 2019. For personal use only. No other uses without permission. 
 Copyright © 2018 Massachusetts Medical Society. All rights reserved. 
Correspondence
n engl j med 379;6 nejm.org August 9, 2018 593
first month, when the effect of withdrawal of 
inhaled glucocorticoids would be greatest.
David A. Lipson, M.D.
GlaxoSmithKline 
Collegeville, PA 
david . a . lipson@ gsk . com
Gerard J. Criner, M.D.
Lewis Katz School of Medicine at Temple University 
Philadelphia, PA
David A. Lomas, M.D., Ph.D.
University College London 
London, United Kingdom
Since publication of their article, the authors report no fur-
ther potential conflict of interest.
1. Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol–
glycopyrronium versus salmeterol–fluticasone for COPD. N Engl 
J Med 2016; 374: 2222-34.
2. Global Initiative for Chronic Obstructive Lung Disease 
(GOLD). Global strategy for the diagnosis, management and 
prevention of COPD. 2018 (https://goldcopd .org/ wp - content/ 
uploads/ 2017/ 11/ GOLD - 2018 - v6 .0 - FINAL - revised - 20 - Nov_WMS 
.pdf).
3. Tinkelman DG, Price DB, Nordyke RJ, Halbert RJ. Misdiag-
nosis of COPD and asthma in primary care patients 40 years of 
age and over. J Asthma 2006; 43: 75-80.
4. Celli BR, MacNee W. Standards for the diagnosis and treat-
ment of patients with COPD: a summary of the ATS/ERS position 
paper. Eur Respir J 2004; 23: 932-46.
DOI: 10.1056/NEJMc1807380
Adjuvant Pembrolizumab in Resected Stage III Melanoma
To the Editor: In the past 2 years, Eggermont 
et al. have reported the findings of two landmark 
trials of adjuvant immunotherapy for stage III 
melanoma: the European Organization for the 
Research and Treatment of Cancer (EORTC) 18071 
trial of ipilimumab1 and the EORTC 1325 trial of 
pembrolizumab (May 10 issue).2 Both trials sug-
gest that adjuvant immunotherapy had a smaller 
effect on preventing locoregional recurrence than 
on preventing distant metastases.
Neither article provides details on regional 
recurrence in patients at high risk for this event, 
such as those with macroscopic involvement of 
large or multiple lymph nodes or those with ex-
tracapsular extension. In the EORTC 1325 trial, 
hazard ratios for recurrence were higher for pa-
tients with high-risk lymph-node metastases 
(stages IIIB and IIIC, macroscopic nodes, and ≥4 
positive nodes) than for those with low-risk 
lymph-node metastases (stage IIIA, microscopic 
nodes, and ≤3 positive nodes). Regional recur-
rence after lymphadenectomy may be mitigated 
by lymph node–directed radiation therapy3; it 
would be helpful to know whether adjuvant im-
munotherapy obviates the need for this. In the 
Discussion section of their current article, Egger-
mont et al. suggest that less intensive therapy 
may be appropriate for patients with melanoma 
who have low-risk lymph-node metastasis.4 How-
ever, for patients with high-risk lymph-node 
metastases, further study of more effective treat-
ments associated with fewer adverse events may 
be warranted.
Christopher A. Barker, M.D.
Memorial Sloan Kettering Cancer Center 
New York, NY 
barkerc@ mskcc . org
Dr. Barker reports that his institution receives research fund-
ing from Merck, Amgen, and Bristol-Myers Squibb for clinical 
trials that he leads or is participating in as an investigator. No 
other potential conflict of interest relevant to this letter was re-
ported.
1. Eggermont AMM, Chiarion-Sileni V, Grob J-J, et al. Prolonged 
survival in stage III melanoma with ipilimumab adjuvant therapy. 
N Engl J Med 2016; 375: 1845-55.
2. Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant 
pembrolizumab versus placebo in resected stage III melanoma. 
N Engl J Med 2018; 378: 1789-801.
3. Henderson MA, Burmeister BH, Ainslie J, et al. Adjuvant 
lymph-node field radiotherapy versus observation only in pa-
tients with melanoma at high risk of further lymph-node field 
relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 
6-year follow-up of a phase 3, randomised controlled trial. Lancet 
Oncol 2015; 16: 1049-60.
4. Faries MB, Thompson JF, Cochran AJ, et al. Completion dis-
section or observation for sentinel-node metastasis in melanoma. 
N Engl J Med 2017; 376: 2211-22.
DOI: 10.1056/NEJMc1807505
The authors reply: In reply to Barker: the median 
follow-up was 1.3 years in the EORTC 1325 trial of 
pembrolizumab and 5.3 years in the EORTC 18071 
trial of ipilimumab.1 Table 1 shows, for each trial 
according to treatment group, the number of pa-
tients who had a recurrence-free survival event 
(locoregional recurrence, distant recurrence, or 
both, or death without a reported recurrence), 
the 1.5-year estimate of recurrence-free survival 
rates for both trials, the 5-year estimate of the 
recurrence-free survival rate in the EORTC 18071 
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